Aclara Research Leads Medical Cannabis Industry
with Release of Largest Illinois Patient Study
Study
Showcases Positive Impact of Medical Cannabis among Patients and Health Care
Industry
Chicago,
IL - May 23, 2017 (Investorideas.com Newswire) Aclara Research, a leader in the
development of patient and consumer insights within the medical cannabis
industry, today released the results of The Illinois Medical Cannabis Patient
Experience Study - the first of Illinois patients since the inception of the
pilot program in 2012. The study is the largest and most comprehensive look at
the impact of the statewide program, examining nearly 300 of the 18,000
Illinois residents registered.
The
Aclara Research study found that 86 percent of survey respondents are managing
leading symptoms of chronic pain. While chronic pain is not one of the 41
qualifying conditions in Illinois, cannabis shows strong potential in treating
autoimmune diseases in which chronic inflammation plays a central role.
Read this
news in full at http://www.investorideas.com/news/2017/marijuana/05231Illinois.asp
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third
party sourced news, articles and equity research as well as creates original
content, including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated for news
publication and distribution, social media and marketing, content creation and
more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional
info regarding BC Residents and global Investors: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
No comments:
Post a Comment